Madrigal Pharma (MDGL) Tops Q2 EPS by $1.73, Beats on Revenue

Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($1.90), $1.73 better than the analyst estimate of ($3.63). Revenue for the quarter came in at $212.8 million versus the consensus estimate of $159.45 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• eToro Group (ETOR) Reiterated at Overweight by Cantor Fitzgerald
• Lazard hires new head of defense and emerging technology
• Paramount, Warner Bros jump on report of settlement progress in merger fight